title: The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
abstract: Pegylated liposomal doxorubicin (PLD) is an effective and tolerable agent in the treatment of recurrent and refractory ovarian carcinoma. One of the most common dose-limiting toxicities of PLD is palmar-plantar erythrodysesthesia (PPE). We report a retrospective review of patients who took cod liver oil (CLO) while being treated with PLD at Roswell Park Cancer Institute. None of the patients required dose reduction, treatment interruption or discontinuation secondary to skin toxicity. No patient experienced grade 2 or greater PPE. The mechanism for the development of PLD-induced PPE is unknown. CLO may possibly mitigate it via decreased extravasation of PLD and/or by a blunting of the local inflammatory response. The effects of CLO should be further evaluated in a prospective, randomized trial, and attempts to elucidate the mechanism by which CLO may exert its effects should be pursued.
authors.affiliation: University at Buffalo School of Medicine, Buffalo, NY, USA.
authors.forename: M
authors.initials: M
authors.lastname: Kanis
authors.forename: J P
authors.initials: JP
authors.lastname: Kesterson
authors.forename: S
authors.initials: S
authors.lastname: Lele
mesh_terms: D000284:Administration, Oral; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D003060:Cod Liver Oil / Q000008:administration & dosage*; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology / Q000517:prevention & control*; D004890:Erythema / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D005533:Foot Dermatoses / Q000139:chemically induced / Q000517:prevention & control*; D006229:Hand Dermatoses / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010292:Paresthesia / Q000139:chemically induced / Q000517:prevention & control; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D003060:Cod Liver Oil; D004317:Doxorubicin